BridgeBio Pharma, Inc. (FRA:2CL)
Germany · Delayed Price · Currency is EUR 63.52
-1.44 (-2.22%)
Last updated: Jan 28, 2026, 3:58 PM CET
BridgeBio Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 353.78 | 221.9 | 9.3 | 77.65 | 69.72 | 8.25 | |
Revenue Growth (YoY) | 62.46% | 2285.27% | -88.02% | 11.38% | 745.14% | -79.66% |
Cost of Revenue | 14.94 | 3.88 | 2.45 | 3.43 | 3.11 | - |
Gross Profit | 338.84 | 218.02 | 6.86 | 74.21 | 66.6 | 8.25 |
Selling, General & Admin | 451.42 | 272.43 | 150.59 | 143.19 | 188.91 | 145.68 |
Research & Development | 465.89 | 506.46 | 455.71 | 399.46 | 451.02 | 337.05 |
Operating Expenses | 917.31 | 778.89 | 606.3 | 542.65 | 639.93 | 482.73 |
Operating Income | -578.47 | -560.87 | -599.44 | -468.44 | -573.33 | -474.48 |
Interest Expense | -157.75 | -99.29 | -81.29 | -80.44 | -46.78 | -36.66 |
Interest & Investment Income | 20.21 | 17.25 | 18.04 | 7.54 | 1.13 | 4.01 |
Earnings From Equity Investments | -68.27 | -31.18 | - | - | - | - |
Other Non Operating Income (Expenses) | 32.86 | 4.14 | 0.3 | 102.43 | 3.7 | 1.63 |
EBT Excluding Unusual Items | -751.42 | -669.96 | -662.4 | -438.9 | -615.28 | -505.49 |
Merger & Restructuring Charges | -15.18 | -15.61 | -7.93 | -43.77 | - | - |
Gain (Loss) on Sale of Investments | - | 8.14 | 18.31 | -8.22 | 29.91 | - |
Gain (Loss) on Sale of Assets | - | 178.32 | -1.24 | -6.26 | - | - |
Asset Writedown | 0.27 | - | - | - | -3.3 | - |
Other Unusual Items | -37.66 | -43.09 | - | 12.5 | 2.21 | - |
Pretax Income | -803.98 | -542.19 | -653.25 | -484.65 | -586.45 | -505.49 |
Income Tax Expense | 1.71 | 1.15 | - | - | - | - |
Earnings From Continuing Operations | -805.69 | -543.35 | -653.25 | -484.65 | -586.45 | -505.49 |
Minority Interest in Earnings | 8.57 | 7.59 | 10.05 | 3.47 | 23.92 | 56.76 |
Net Income | -797.12 | -535.76 | -643.2 | -481.18 | -562.54 | -448.72 |
Net Income to Common | -797.12 | -535.76 | -643.2 | -481.18 | -562.54 | -448.72 |
Shares Outstanding (Basic) | 190 | 186 | 163 | 147 | 144 | 118 |
Shares Outstanding (Diluted) | 190 | 186 | 163 | 147 | 144 | 118 |
Shares Change (YoY) | 4.48% | 14.30% | 10.39% | 2.16% | 22.34% | 12.27% |
EPS (Basic) | -4.18 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 |
EPS (Diluted) | -4.18 | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 |
Free Cash Flow | -585.93 | -521.66 | -529.03 | -424.32 | -511.18 | -407.23 |
Free Cash Flow Per Share | -3.08 | -2.80 | -3.25 | -2.88 | -3.54 | -3.45 |
Gross Margin | 95.78% | 98.25% | 73.71% | 95.58% | 95.53% | 100.00% |
Operating Margin | -163.51% | -252.76% | -6443.56% | -603.28% | -822.38% | -5751.99% |
Profit Margin | -225.32% | -241.44% | -6913.92% | -619.70% | -806.90% | -5439.74% |
Free Cash Flow Margin | -165.62% | -235.08% | -5686.62% | -546.46% | -733.23% | -4936.74% |
EBITDA | -573.1 | -554.79 | -592.95 | -461.67 | -567.49 | -473.03 |
EBITDA Margin | -161.99% | -250.02% | - | - | - | - |
D&A For EBITDA | 5.37 | 6.08 | 6.49 | 6.77 | 5.84 | 1.46 |
EBIT | -578.47 | -560.87 | -599.44 | -468.44 | -573.33 | -474.48 |
EBIT Margin | -163.51% | -252.76% | - | - | - | - |
Revenue as Reported | 131.88 | - | - | - | - | 8.25 |
Advertising Expenses | - | 21.5 | - | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.